UK's MHRA authorises Redemplo for adults with familial chylomicronaemia syndrome
ARWR•The UK's MHRA authorised plozasiran, marketed as Redemplo, for adults with familial chylomicronaemia syndrome.
1. UK authorisation
The UK's Medicines and Healthcare products Regulatory Agency authorised plozasiran, marketed as Redemplo, for adults with familial chylomicronaemia syndrome.
